Cancer Biology & Medicine

Papers
(The TQCC of Cancer Biology & Medicine is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
Mitochondrial transplantation sensitizes chemotherapy to inhibit tumor development by enhancing anti-tumor immunity173
Eliminating cervical cancer: a global health imperative for women95
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up57
The Warburg effect drives dedifferentiation through epigenetic reprogramming52
Early-onset gastric cancer global burden profile, trends, and contributors52
Optimizing the cancer research landscape for the benefit of patients and society: A strategic perspective of the German Cancer Research Center (DKFZ) and its partnerships with university medical cente43
Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II tria41
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC40
Cancer-derived exosomal circTMEM56 enhances the efficacy of HCC radiotherapy through the miR-136-5p/STING axis38
Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer37
Associations between polymorphisms in leptin and leptin receptor genes and colorectal cancer survival37
Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies33
PD-1 inhibitors provide new opportunities in conversion therapy for stage IV gastric cancer32
ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis32
ENO1 expression and Erk phosphorylation in PDAC and their effects on tumor cell apoptosis in a hypoxic microenvironment29
Cancer stem cells: a target for overcoming therapeutic resistance and relapse28
A machine learning model to predict efficacy of neoadjuvant therapy in breast cancer based on dynamic changes in systemic immunity25
Immune checkpoint inhibitors: breakthroughs in cancer treatment25
Cancer cell-derived migrasomes harboring ATF6 promote breast cancer brain metastasis via endoplasmic reticulum stress-mediated disruption of the blood-brain barrier23
Effects of Helicobacter pylori eradication on the profiles of blood metabolites and their associations with the progression of gastric lesions: a23
Advances in lung cancer screening and early detection22
Nodal peripheral T-cell lymphomas in the new classification systems21
Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study21
Ubiquitination in osteosarcoma: unveiling the impact on cell biology and therapeutic strategies19
Conceptualizing the complexity of ferroptosis to treat triple-negative breast cancer: theory-to-practice19
Facing challenges with hope: universal immune cells for hematologic malignancies19
Intricate roles of estrogen and estrogen receptors in digestive system cancers: a systematic review18
Biological insights in non-small cell lung cancer18
Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study17
Human papillomavirus vaccination willingness under resource inequities: momentary intervention effects of an educational video17
A quick and reliable image-based AI algorithm for evaluating cellular senescence of gastric organoids16
Progress toward cervical cancer elimination: global disparities and China’s contributions16
The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma16
Elucidating the synergistic roles of CD4+ T and dendritic cells in antitumor immunity16
Advances in antibody-drug conjugates for urothelial carcinoma treatment15
First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects15
PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer15
Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer14
Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer14
Current and future trends in whole genome sequencing in cancer14
Perspective on novel proteins encoded by circular RNAs in glioblastoma13
Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma12
Deep proteome profiling promotes whole proteome characterization and drug discovery for esophageal squamous cell carcinoma11
Research progress in tumor angiogenesis and drug resistance in breast cancer11
Liquid-liquid phase separation in DNA double-strand break repair11
Treatment strategies for patients with HER2-positive gastric cancer11
BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibi10
PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas10
CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy10
Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer10
Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer10
The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer10
Immunological and metabolic optimization of tumor neoantigen vaccines10
Major roles of the circadian clock in cancer10
From dichotomy to diversity: deciphering the multifaceted roles of tumor-associated macrophages in cancer progression and therapy10
Anti-tumor pharmacology of natural products targeting mitosis10
A causal variant rs3769823 in 2q33.1 involved in apoptosis pathway leading to a decreased risk of non-small cell lung cancer10
The evidence and concerns about screening ultrasound for breast cancer9
Cancer risk in relatives of BRCA1/2 pathogenic variant carriers in a large series of unselected patients with breast cancer9
Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window9
Single-arm trials for domestic oncology drug approvals in China9
Current status of management of immune-related adverse events and practical needs for oncologist education9
Next-generation antibody–drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer9
Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy9
Drug clinical trials on high-grade gliomas: challenges and hopes9
N6-methyladenosine (m6A) RNA modification in tumor immunity8
Understanding the mechanisms underlying obesity in remodeling the breast tumor immune microenvironment: from the perspective of inflammation8
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification8
Comparative profiling of immune genes improves the prognoses of lower grade gliomas8
Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy8
Early detection of gastric cancer in China: progress and opportunities8
MicroRNA-384 radiosensitizes human non-small cell lung cancer by impairing DNA damage response and repair signaling, which is inhibited by NF-κB8
The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer8
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation8
Metabolic regulation of immune responses to cancer8
Treatment strategies for advanced neuroendocrine neoplasms: current status and future prospects7
Decoding the complexity of metastasis7
Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer7
Mutations in Ras homolog family member A in patients with peripheral T-cell lymphoma and implications for personalized medicine7
Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors7
Epigenetic regulators as the foundation for molecular classification of colorectal cancer7
Development of glioblastoma organoids and their applications in personalized therapy7
Erianin inhibits the proliferation of lung cancer cells by suppressing mTOR activation and disrupting pyrimidine metabolism7
A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer7
Large-scale loss-of-function perturbations reveal a comprehensive epigenetic regulatory network in breast cancer7
Targeting PP2A for cancer therapeutic modulation7
MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis7
Genomic medicine in clinical practice: national genomic medicine program in Japan6
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells6
Senescent macrophages in cancer: roles in tumor progression and treatment opportunities6
Integrated pretreatment stratification system for pancreatic cancer: combining anatomical resectability and tumor biological parameters6
Immunotherapy for multiple myeloma: new chances and hope6
Global, regional, and national burden of early-onset gastric cancer6
Erratum to Treatment strategies for patients with HER2-positive gastric cancer6
Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP6
Therapeutic perspectives for adult soft tissue sarcoma—updates from the 2022 ASCO annual meeting6
Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma6
Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?6
The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer6
Extracellular vesicle-mediated heterogeneous communication between cancer and the lymphatic system facilitates lymphatic metastasis6
Neoantigen cancer vaccines: a new star on the horizon6
The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan6
Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy6
0.062179803848267